Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses

<p><strong>Background:</strong> The aim of this case study is to compare the effectiveness between cyclophosphamide and mycophenolate mofetil to achieve remission of lupus nephritis in an evidence-based case report from meta-analyses.<br /><strong></strong></p&...

Full description

Bibliographic Details
Main Authors: Laurentius A. Pramono, Birry Karim, Wulyo Rajabto, Parlindungan Siregar, Nanang Sukmana, Bambang Setyohadi
Format: Article
Language:English
Published: Faculty of Medicine Universitas Indonesia 2012-02-01
Series:Medical Journal of Indonesia
Online Access:http://mji.ui.ac.id/journal/index.php/mji/article/view/474
id doaj-5b38b19628b24306ac3e681ac5a2e5eb
record_format Article
spelling doaj-5b38b19628b24306ac3e681ac5a2e5eb2020-11-25T02:17:48ZengFaculty of Medicine Universitas Indonesia Medical Journal of Indonesia0853-17732252-80832012-02-01211445110.13181/mji.v21i1.474471Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analysesLaurentius A. PramonoBirry KarimWulyo RajabtoParlindungan SiregarNanang SukmanaBambang Setyohadi<p><strong>Background:</strong> The aim of this case study is to compare the effectiveness between cyclophosphamide and mycophenolate mofetil to achieve remission of lupus nephritis in an evidence-based case report from meta-analyses.<br /><strong></strong></p><p><strong>Methods:</strong> Method in this case study is evidence-based case report using meta-analyses. Clinical question used in this paper is; which immunosuppressant gives better result in achieving remission in lupus nephritis patient: cyclophosphamide or mycophenolate mofetil? To answer this question, we search the evidence from PubMed with the keywords: “lupus nephritis AND mycophenolate mofetil AND cyclophosphamide” with inclusion criteria of meta-analysis, written in English, and focused comparing cyclophosphamide and mycophenolate mofetil.<br /><strong></strong></p><p><strong>Results:</strong> From the searching method, we found 11 articles which is relevant. One has been excluded since it written in Hebrew, 4 articles excluded since are not focus answering the clinical question. At the end, 6 studies were included to the critical appraisal step.<br /><strong></strong></p><p><strong>Conclusion:</strong> Based on the evidences, mycophenolate mofetil is non-inferior to cyclophosphamide in achieving remission in lupus nephritis patients, but with the better safety profile. Patient in our case study get mycophenolate mofetil and shows better clinical condition towards remission as she are evaluated in the outpatient clinic. <em><strong>(Med J Indones 2012;21:44-51)</strong></em></p><p><strong>Keywords:</strong> <em>Cyclophosphamide, evidence-based case report, lupus nephritis, meta-analysis, mycophenolate mofetil, remission, systematic review</em></p>http://mji.ui.ac.id/journal/index.php/mji/article/view/474
collection DOAJ
language English
format Article
sources DOAJ
author Laurentius A. Pramono
Birry Karim
Wulyo Rajabto
Parlindungan Siregar
Nanang Sukmana
Bambang Setyohadi
spellingShingle Laurentius A. Pramono
Birry Karim
Wulyo Rajabto
Parlindungan Siregar
Nanang Sukmana
Bambang Setyohadi
Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses
Medical Journal of Indonesia
author_facet Laurentius A. Pramono
Birry Karim
Wulyo Rajabto
Parlindungan Siregar
Nanang Sukmana
Bambang Setyohadi
author_sort Laurentius A. Pramono
title Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses
title_short Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses
title_full Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses
title_fullStr Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses
title_full_unstemmed Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses
title_sort mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses
publisher Faculty of Medicine Universitas Indonesia
series Medical Journal of Indonesia
issn 0853-1773
2252-8083
publishDate 2012-02-01
description <p><strong>Background:</strong> The aim of this case study is to compare the effectiveness between cyclophosphamide and mycophenolate mofetil to achieve remission of lupus nephritis in an evidence-based case report from meta-analyses.<br /><strong></strong></p><p><strong>Methods:</strong> Method in this case study is evidence-based case report using meta-analyses. Clinical question used in this paper is; which immunosuppressant gives better result in achieving remission in lupus nephritis patient: cyclophosphamide or mycophenolate mofetil? To answer this question, we search the evidence from PubMed with the keywords: “lupus nephritis AND mycophenolate mofetil AND cyclophosphamide” with inclusion criteria of meta-analysis, written in English, and focused comparing cyclophosphamide and mycophenolate mofetil.<br /><strong></strong></p><p><strong>Results:</strong> From the searching method, we found 11 articles which is relevant. One has been excluded since it written in Hebrew, 4 articles excluded since are not focus answering the clinical question. At the end, 6 studies were included to the critical appraisal step.<br /><strong></strong></p><p><strong>Conclusion:</strong> Based on the evidences, mycophenolate mofetil is non-inferior to cyclophosphamide in achieving remission in lupus nephritis patients, but with the better safety profile. Patient in our case study get mycophenolate mofetil and shows better clinical condition towards remission as she are evaluated in the outpatient clinic. <em><strong>(Med J Indones 2012;21:44-51)</strong></em></p><p><strong>Keywords:</strong> <em>Cyclophosphamide, evidence-based case report, lupus nephritis, meta-analysis, mycophenolate mofetil, remission, systematic review</em></p>
url http://mji.ui.ac.id/journal/index.php/mji/article/view/474
work_keys_str_mv AT laurentiusapramono mycophenolatemofetilversuscyclophosphamidefortherapyoflupusnephritisanevidencebasedcasereportfromsystematicreviewsandmetaanalyses
AT birrykarim mycophenolatemofetilversuscyclophosphamidefortherapyoflupusnephritisanevidencebasedcasereportfromsystematicreviewsandmetaanalyses
AT wulyorajabto mycophenolatemofetilversuscyclophosphamidefortherapyoflupusnephritisanevidencebasedcasereportfromsystematicreviewsandmetaanalyses
AT parlindungansiregar mycophenolatemofetilversuscyclophosphamidefortherapyoflupusnephritisanevidencebasedcasereportfromsystematicreviewsandmetaanalyses
AT nanangsukmana mycophenolatemofetilversuscyclophosphamidefortherapyoflupusnephritisanevidencebasedcasereportfromsystematicreviewsandmetaanalyses
AT bambangsetyohadi mycophenolatemofetilversuscyclophosphamidefortherapyoflupusnephritisanevidencebasedcasereportfromsystematicreviewsandmetaanalyses
_version_ 1724884952253726720